Published in:
01-09-2010 | Commentary
Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations
Authors:
J. A. Johnson, Y. Yasui
Published in:
Diabetologia
|
Issue 9/2010
Login to get access
Excerpt
The potential role of glucose-lowering therapies in modulating the relationship between diabetes and cancer has seemingly exploded into our collective consciousness in the past year. While this relationship has been suggested for sometime [
1‐
3], the recent surge in attention followed publication of several observational studies from European administrative registries and clinical databases [
4‐
7]. This prompted a number of editorials and commentaries, most often critical of the observational nature of the reports, as well as critical of limitations in the analytic approach to those data [
8‐
11]. Further, as is often the case with controversial reports from observational studies, calls were made to look to a higher level of evidence, such as data from randomised controlled trials. …
